ArticleThe Journal of infectious diseases2016
Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2022Pooled it
- Development of an immunochromatographic lateral flow assay for the rapid detection of all known orthoebolavirus glycoproteins.Npj viruses · 2026Article
- Invisible and undervalued: A qualitative study of laboratory workers' experiences and perceptions of laboratory strengthening in Sierra Leone.African journal of laboratory medicine · 2024Article
- Technologies for Frugal and Sensitive Point-of-Care Immunoassays.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.Science translational medicine · 2021Article
- Boosting understanding of Lassa Fever virus epidemiology: Field testing a novel assay to identify past Lassa Fever virus infection in blood and oral fluids of survivors and unexposed controls in Sierra Leone.PLoS neglected tropical diseases · 2021Article
- Early detection of Ebola virus proteins in peripheral blood mononuclear cells from infected mice.Clinical proteomics · 2020Article
- Diagnostic Laboratories' Capacities and Preparedness for Emerging Viral Diseases in Guinea and Mali.Infectious diseases diagnosis & treatment · 2020Article
- A Smartphone-Based Rapid Telemonitoring System for Ebola and Marburg Disease Surveillance.ACS sensors · 2019Article
- Tracking virus outbreaks in the twenty-first century.Nature microbiology · 2019Review
- Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia.BMJ global health · 2019Article
- Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings.BMJ global health · 2019Article
- Development of Mobile Laboratory for Viral Hemorrhagic Fever Detection in Africa.The Journal of infectious diseases · 2018Article
- Analysis of CD8Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Article
- Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.Scientific reports · 2018Article
- Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.PLoS neglected tropical diseases · 2017Article
- Epidemiology and Management of the 2013-16 West African Ebola Outbreak.Annual review of virology · 2016Review
- Responding to ever-changing epidemiological dynamics of Ebola virus disease.BMJ global health · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundThe 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) could exceed 5 days. Here we describe the development and field validation of the ReEBOV Antigen Rapid Test (ReEBOV RDT) to aid triage of individuals with suspected EVD.
methodsSamples from patients with suspected EVD were submitted to Kenema Government Hospital, Sierra Leone, for Lassa fever and EVD screening throughout 2014. Banked residual clinical samples were tested in November 2014 and January 2015 in a blinded field trial to estimate the clinical effectiveness of the ReEBOV RDT, compared with EBOV-specific qRT-PCR.
resultsPreliminary ReEBOV RDT performance demonstrated a positive percentage agreement (PPA) of 91.1% (195 of 214 results; 95% confidence interval [CI], 86.5%-94.6%) and a negative percentage agreement (NPA) of 90.2% (175 of 194; 95% CI, 85.1%-94.0%). The final estimates used by the Food and Drug Administration to determine whether to grant emergency use authorization for the test, which excluded a qRT-PCR reference method threshold cutoff, were a PPA of 62.1% (72 of 116 results; 95% CI, 52.6%-70.9%) and a NPA of 96.7% (58 of 60; 95% CI, 88.5%-99.6%), with a diagnostic likelihood of 18.6. A subsequent, independent evaluation by the World Health Organization generated results consistent with the preliminary performance estimates.
conclusionsThe ReEBOV RDT demonstrated the potential to provide clinically effective rapid and accurate point-of-care test results and, thus, to be a powerful tool for increasing triage efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.